NCT00734890: Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma |
|
|
| Completed | 1 | 18 | US | bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 06/10 | 02/11 | | |
